Any prior Alzheimer's Data Like Sava's Recent Data?
In Feb 2021, $SAVA reported impressive results from an open label study of its drug Sumifilam, in the first 50 patients at 6 months, which showed not only a slowing/stopping of cognition decline and dementia related behavior, but an actual improvement (See the IQ Card). There was no mention of statistical analysis that I could find, and maybe the patient numbers are too low and timepoint too early. In its press release, SAVA shows label data from aducanumab, showing a decline in cognition at 6 months in their phase 3 trial (>1,000 patients). We are looking forward to the further data update in mid-2021 and are surpised that their options volatility/Big Mover score is not higher currently. This suggests that it might be a good time to buy call options if you think the stock will move more than the market does, on this mid-2021 update.
Are you aware of any other drugs besides Sumifilam that have showed an improvement in cognition and dementia in Alzheimer's patients, even in an open label, 6 month trial?
$Casava #SAVA #Casava #Sumifilam #Sumi #Alzheimers